JP2013541528A - ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置 - Google Patents

ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置 Download PDF

Info

Publication number
JP2013541528A
JP2013541528A JP2013529441A JP2013529441A JP2013541528A JP 2013541528 A JP2013541528 A JP 2013541528A JP 2013529441 A JP2013529441 A JP 2013529441A JP 2013529441 A JP2013529441 A JP 2013529441A JP 2013541528 A JP2013541528 A JP 2013541528A
Authority
JP
Japan
Prior art keywords
polypeptide
engineered
residue
binding
glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013529441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013541528A5 (https=
Inventor
ラフル ラマン，
シャオイン コー，
カーシック ビスワナザン，
ラム サシセカーラン，
アーティー チャンドラセカラン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2013541528A publication Critical patent/JP2013541528A/ja
Publication of JP2013541528A5 publication Critical patent/JP2013541528A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
JP2013529441A 2010-09-21 2011-09-21 ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置 Pending JP2013541528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38478010P 2010-09-21 2010-09-21
US61/384,780 2010-09-21
PCT/US2011/052670 WO2012040406A2 (en) 2010-09-21 2011-09-21 Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016030487A Division JP2016094484A (ja) 2010-09-21 2016-02-19 ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置

Publications (2)

Publication Number Publication Date
JP2013541528A true JP2013541528A (ja) 2013-11-14
JP2013541528A5 JP2013541528A5 (https=) 2014-11-13

Family

ID=45874368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013529441A Pending JP2013541528A (ja) 2010-09-21 2011-09-21 ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
JP2016030487A Pending JP2016094484A (ja) 2010-09-21 2016-02-19 ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016030487A Pending JP2016094484A (ja) 2010-09-21 2016-02-19 ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置

Country Status (6)

Country Link
US (3) US8802110B2 (https=)
EP (1) EP2640405A4 (https=)
JP (2) JP2013541528A (https=)
AU (1) AU2011305371B2 (https=)
CA (1) CA2811023A1 (https=)
WO (1) WO2012040406A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US10526375B2 (en) 2013-06-05 2020-01-07 Massachusetts Institute Of Technology Human Adaptation of H7 HA
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP3731862A1 (en) * 2017-12-29 2020-11-04 Development Center for Biotechnology A universal vaccine against influenza
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3976083A4 (en) * 2019-05-31 2023-07-12 iBio, Inc. MACHINE LEARNING BASED DEVICE FOR THE DEVELOPMENT OF MESO-SCALE PEPTIDES, AND METHOD AND SYSTEM THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089119A2 (en) * 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies
JP2010500880A (ja) * 2006-08-14 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー ヘマグルチニンポリペプチド、ならびにヘマグルチニンポリペプチドに関連する試薬および方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4692411A (en) 1983-09-06 1987-09-08 Ghose Rabindra N Separation of specific biological cells by a biochemical filter
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
JP5008244B2 (ja) 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2006108226A1 (en) 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP1998814A4 (en) 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20090081193A1 (en) * 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008040060A1 (en) 2006-10-04 2008-04-10 The University Of Queensland Vlp based vaccine delivery system
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008148104A1 (en) 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
HUE025702T2 (en) 2007-07-19 2016-04-28 Novavax Inc Avian Flu Chimeric VLPs
CA2711334A1 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
MX370690B (es) 2008-07-18 2019-12-19 Medicago Inc Epitopo de inmunizacion de nuevo virus de la influenza.
CN102361649A (zh) * 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500880A (ja) * 2006-08-14 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー ヘマグルチニンポリペプチド、ならびにヘマグルチニンポリペプチドに関連する試薬および方法
JP2010501074A (ja) * 2006-08-14 2010-01-14 マサチューセッツ・インスティテュート・オブ・テクノロジー グリカンのデータマイニングシステム
WO2009089119A2 (en) * 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 5, no. 6, JPN6015042033, June 2010 (2010-06-01), pages 11158 - 1, ISSN: 0003178442 *

Also Published As

Publication number Publication date
US20180009850A1 (en) 2018-01-11
JP2016094484A (ja) 2016-05-26
US20120219585A1 (en) 2012-08-30
AU2011305371A1 (en) 2013-05-02
US20150147329A1 (en) 2015-05-28
AU2011305371B2 (en) 2015-05-21
EP2640405A2 (en) 2013-09-25
US8802110B2 (en) 2014-08-12
CA2811023A1 (en) 2012-03-29
EP2640405A4 (en) 2015-04-15
WO2012040406A2 (en) 2012-03-29
WO2012040406A3 (en) 2012-08-09
US9745352B2 (en) 2017-08-29

Similar Documents

Publication Publication Date Title
JP6143902B2 (ja) 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法
JP2016094484A (ja) ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
US9709567B2 (en) Compositions and methods for diagnosing and/or treating influenza infection
JP6518597B2 (ja) Ｈ５インフルエンザのヒトへの適応
US20090269342A1 (en) Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
CN101553502A (zh) 血球凝集素多肽和其相关试剂和方法
BR112015018503B1 (pt) Polipeptídeo hemaglutinina (ha) h5, composição de vacina, método para fornecer uma vacina e kit de diagnóstico
HK1218923B (en) Human adaptation of h5 influenza

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160523